Athersys, Inc. (ATHX)
(Delayed Data from NSDQ)
$1.55 USD
+0.04 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.55 USD
+0.04 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.55 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal
by Zacks Equity Research
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
by Zacks Equity Research
The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.
Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies
by Zacks Equity Research
Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.
Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM
by Zacks Equity Research
The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
by Zacks Equity Research
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.
Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why
by Zacks Equity Research
Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
by Zacks Equity Research
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA
by Zacks Equity Research
Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.
Horizon's (HZNP) sBLA for Krystexxa Gets FDA Priority Review
by Zacks Equity Research
The FDA grants priority review to Horizon's (HZNP) sBLA for Krystexxa plus methotrexate to treat people living with uncontrolled gout. A decision is due on Jul 7, 2022.
Is Athersys, Inc. (ATHX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Athersys, Inc. (ATHX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amneal Pharmaceuticals (AMRX) and Athersys, Inc. (ATHX) have performed compared to their sector so far this year.
Implied Volatility Surging for Athersys (ATHX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Athersys, Inc. (ATHX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Investors Should Hold on to Universal Health (UHS) Stock
by Zacks Equity Research
Universal Health (UHS) can bank on balance sheet strength for future acquisitions to grow its business inorganically.
Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Athersys (ATHX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Athersys, Inc. (ATHX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Athersys (ATHX) Surges: Stock Moves 8.8% Higher
by Zacks Equity Research
Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
Athersys Gets FDA's RMAT Designation for Cell Therapy in ARDS
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.
New Strong Sell Stocks for August 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
Pluristem Up on Cell Therapy Treatment of Coronavirus Patient
by Zacks Equity Research
Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
by Ekta Bagri
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.